The 2014 American Urological Association (AUA) Urological Oncology Symposium, “Progress in Translational Urological Oncology”, will be held at the 2014 AUA Annual Meeting in Orlando, Florida on Friday, May 16, 2014 from 8 a.m. – 5 p.m. There will be two central themes offered this year, one in the morning and one in the afternoon. The morning theme will focus on progress arising from the prostate cancer SPOREs with an emphasis on differentiation of indolent versus aggressive prostate cancer, and the afternoon theme will focus on progress from the renal and bladder SPOREs. The goals of both sessions are to catalyze translation of laboratory findings into clinical settings and vice-versa.
This conference is unique in that it is the first session at the AUA Annual Meeting that will be specifically devoted to the themes and progress made by the NCI Genitourinary Spore Program. The AUA Annual Meeting provides the most attractive opportunity for a forum to present this information to the nearly 5,000 AUA members that identify urological oncology as an area of special interest.
The intent of the symposium is to create synergies and foster collaboration in genitourinary oncology by bringing together scientists and clinicians at all career levels in a stimulating and interactive setting. The information discussed and shared during this meeting is expected to catalyze the translation of laboratory research to practical application. It is also intended to serve as a forum where young investigators have the opportunity to meet and interact with leaders in a host of disciplines related to prostate, bladder and kidney cancer. By learning more about these topics and the future of team science and personalized medicine from the most respected scientists in the world, all attendees will benefit from the state-of-the-art information provided and will become better equipped to formulate novel translational approaches that will lead to novel, impactful and effective treatments.
The meeting agenda is organized into two major topic sessions and a closing Special Topic Keynote presentation. Ample time will be allotted for question and answer periods and networking. Speakers will consist of leaders drawn from the three Genitourinary SPOREs.
Leaders of the AUA and its affiliated specialty societies, including the Society of Urologic Oncology (SUO) and the Society for Basic Urologic Research (SBUR) will be invited to attend. Scientific and program officers from the National Cancer Institute will also be invited to attend.